Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Justin P. Fairchild"'
Autor:
Jaclyn Paige Lyman, Abigail Doucette, Binbin Zheng-Lin, Christopher R. Cabanski, Molly A. Maloy, Nicholas L. Bayless, Jingying Xu, William Smith, Joyson Joseph Karakunnel, Justin P. Fairchild, Ramy Ibrahim, Eileen Mary O'Reilly, Robert H. Vonderheide, Peter Edward Gabriel
Publikováno v:
Journal of Clinical Oncology. 40:528-528
528 Background: ‘Synthetic’ control arms (SCAs), created using electronic health records (EHRs), have immense potential to augment clinical trial findings and provide a rich context of real-world evidence (RWE) while reducing patient (pt) and spo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f075541c315e1bd01159cc7d184701e8
https://doi.org/10.1200/jco.2022.40.4_suppl.528
https://doi.org/10.1200/jco.2022.40.4_suppl.528
Autor:
Tomasz M. Beer, Christopher Logothetis, Padmanee Sharma, Alberto Bossi, Brent McHenry, Justin P. Fairchild, Paul Gagnier, Kevin M. Chin, Jean-Marie Cuillerot, Karim Fizazi, Winald R. Gerritsen
Publikováno v:
Journal of Clinical Oncology. 30:TPS4691-TPS4691
TPS4691 Background: Ipilimumab (Ipi), a fully human monoclonal antibody which blocks CTLA-4, augments antitumor immune responses. Ipi has demonstrated overall survival (OS) benefit in two Phase 3 trials for advanced melanoma, with side effects that w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::180b5bd451a2b9bd79cec51529653c36
https://doi.org/10.1200/jco.2012.30.15_suppl.tps4691
https://doi.org/10.1200/jco.2012.30.15_suppl.tps4691